INITIAL OUTCOMES OF HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HoLEP) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AT 30-4 HOSPITAL
Main Article Content
Abstract
Background: Holmium laser enucleation of the prostate (HoLEP) is considered the new gold standard for the treatment of benign prostatic hyperplasia (BPH) due to its radical enucleation, applicability to all prostate sizes, and long-term efficacy. At 30-4 Hospital, this technique has been recently implemented, necessitating an initial evaluation of its safety and efficacy. Objectives: To evaluate the initial outcomes of Holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia at 30-4 Hospital. To assess the complication rate of this procedure at the hospital. Materials and methods: A retrospective descriptive case series study was conducted on 30 BPH patients who underwent HoLEP at the Department of General Surgery, 30-4 Hospital, from August 2024 to September 2025. Data on patient characteristics, intraoperative parameters, and postoperative outcomes were collected. Results: The median age was 70 (64–74) years; the median prostate volume was 63.5 (32–200) mL; 73.3% of patients were classified as ASA II. The median operative time was 120 minutes (enucleation time: 70 minutes, morcellation time: 10 minutes); the median enucleated tissue weight was 40g. The median catheterization time and postoperative hospital stay were 3 and 4 days, respectively. At 1-month follow-up, the IPSS significantly decreased from 27 to 8 (p < 0.001), and the QoL score improved from 5 to 2. The overall complication rate was 13.3% (postoperative urinary retention and fever accounted for 3.3% each); 2 cases (6.7%) required conversion to open surgery due to morcellator malfunction and bleeding. No urinary incontinence was observed at 1 month. Conclusion: HoLEP is a minimally invasive, safe, and highly effective method for improving BPH-related symptoms, well-applied even in patients with large prostates or underlying comorbidities.
Keywords
Benign prostatic hyperplasia, HoLEP, Holmium laser, 30-4 Hospital
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Campbell-Walsh-Wein Urology. 13th ed. Philadelphia: Elsevier; 2025.
3. Lee H., So S., Cho M.C., Cho S.Y., Paick J.S., et al. Clinical outcomes of holmium laser enucleation of the prostate: A large prospective registry-based patient cohort study under regular follow-up protocol. Investig Clin Urol. 2024. 65(4), 361-367. https://doi.org/10.4111/icu.20240080.
4. Wenk M.J., Hartung F.O., Egen L., Netsch C., Kosiba M., et al. The long-term learning curve of holmium laser enucleation of the prostate (HoLEP) in the en-bloc technique: a single surgeon series of 500 consecutive cases. World J Urol. 2024. 42(1), 436. https://doi.org/10.1007/s00345-024-05097-9.
5. Suh J., Choo M.S., Oh S.J. Efficacy and safety of low power holmium laser enucleation of the prostate: A prospective short- and medium-term single-blind randomized trial. Investig Clin Urol. 2023. 64(5), 480-488. https://doi.org/10.4111/icu.20230017.
6. Sun F., Yao H., Bao X., Wang X., Wang D., et al. The Efficacy and Safety of HoLEP for Benign Prostatic Hyperplasia With Large Volume: A Systematic Review and Meta-Analysis. Am J Mens Health. 2022. 16(4), 15579883221113203. https://doi.org/10.1177/15579883221113203.
7. Li P., Wang C., Tang M., Han P., Meng X. Holmium laser enucleation of prostate by using enbloc and bladder neck preservation technique: technical consideration and influence on functional outcomes. Transl Androl Urol. 2021. 10(1), 134-142. https://doi.org/10.21037/tau20-852.